340B hospitals offer more assistance removing barriers to medication access
New study shows more pharmacy medication access services available at some hospitals
2021-05-06
(Press-News.org) According to a new study published in the journal Research in Social and Administrative Pharmacy, hospitals that participate in the 340B Drug Pricing Program provide more medication access services -- which are services that help remove barriers to accessing necessary medications -- than comparably sized non-340B hospitals.
The University of Illinois Chicago researchers who conducted the study, which included a survey of available services sent to a nationally representative sample of hospitals across the U.S., suggest that 340B participating hospitals may be better positioned to create and administer programs that support patients who are uninsured or underinsured and those who may have job, transportation and other social insecurities.
"Medication access services are an important way that hospitals support patients whose health and wellbeing are dependent on medications but who otherwise may struggle to afford or access drugs. This includes patients with a range of illnesses, from chronic health conditions such as diabetes or hypertension to people who have required life-saving transplants," said Sandra Durley, a clinical assistant professor at the UIC College of Pharmacy in the pharmacy practice and pharmacy systems, outcomes and policy departments.
According to Durley, a contributing author of the study, for low-income patients, the availability of medication access services like prior authorization assistance and provision of free or discounted drugs, for example, at their site of care "can mean the difference between receiving prescribed drug therapy and going without, due to delays or unaffordability of medications."
For the study, researchers collected primary questionnaire response data from pharmacy directors at non-federal acute care hospitals from March 2019 to May 2019. They then assessed the availability of nine medication access service offerings.
There was a significant difference in the average number of services offered between 340B and non-340B hospitals. 340B hospitals offered, on average, 6.2 services while non-340B hospitals offered 3.9 services, after an adjustment for hospital size.
For all nine services that were assessed, a higher percentage of 340B hospitals reported providing the service compared to non-340B hospitals. This difference was statistically significant for six out of the nine services: assistance with prior authorizations (89.7% for 340B hospitals vs. 63.0% for non-340B hospitals), discharge prescription services (85.3% vs. 44.4%), free immunizations (58.8% vs. 33.3%), free or discounted outpatient medications (83.8% vs. 48.2%), medication therapy management (52.9% vs. 11.1%) and patient assistance programs (83.8% vs. 51.9%). There was no statistically significant difference for the other three services: free prescription delivery, free medications from the emergency department and transitions of care.
In addition, the researchers looked at general health care services. For the four services analyzed, an equivalent or higher percentage of 340B hospitals compared with non-340B hospitals reported providing the service. The difference was statistically significant for two of the services: the provision of drug/alcohol outpatient treatment services (37.5% vs. 9.5%) and HIV/AIDS outpatient services (39.3% vs. 9.5%). There was no significant difference for providing free or discounted transportation to health services or providing housing support for homeless patients.
Durley said the data published in this study provides important information for policymakers about how participation in the 340B program translates into expanded services for patients who seek care at safety net and public hospitals.
The authors write, "At a time when 79% of Americans believe that the cost of prescription drugs is unreasonable, and 19% of Americans report not filling a prescription at least once in the last two years due to cost, services that facilitate medication access are imperative for favorable health outcomes. While the 340B Program is not designed in its intent as a direct patient benefit program, its savings can be utilized in a variety of different ways to provide more comprehensive services. The findings of this study suggest that 340B hospitals play a critical role in facilitating medication access."
Durley says that while the survey was conducted before the onset of the COVID-19 pandemic, the data presented in the study is likely just as relevant, if not more relevant, today.
"We've seen increased job loss and social insecurity over the last year that has essentially compounded the barriers experienced by underserved communities who are also bearing the brunt of COVID illness. The pandemic is highlighting that there is a greater need for services that support vulnerable communities, not a lesser need," said Durley, who also is senior associate director of ambulatory care pharmacy services at the University of Illinois Hospital, which participates in the 340B program as a disproportionate share provider.
INFORMATION:
Contributing to the study are first author Isha Rana, now of Houston Methodist; Nadia Nabulsi, Lisa Sharp, Andrew Donnelly and JoAnn Stubbings of UIC; Sima Dinesh Shah of Howard Brown Health; and William von Oehsen of Powers Pyles Sutter & Verville PC.
A grant from Community Voices for 340B, or CV340B, supported the research. CV340B did not participate in the study design, data collection, interpretation or analysis of results.
ELSE PRESS RELEASES FROM THIS DATE:
2021-05-05
Older people with kidney disease have a higher risk of dementia, and the risk increases with the rate and stage of kidney function decline. That is according to a large observational study by researchers at Karolinska Institutet in Sweden, published in the journal Neurology. The findings stress the significance of screening and monitoring for dementia in persons with kidney disease, the researchers say.
"Our study underscores the importance of low kidney function as a possible under-recognized risk factor for dementia," says co-author Juan Jesus Carrero, professor at the Department ...
2021-05-05
With increased media attention and political campaigns focusing on the gender pay gap, the fact that women -- on average -- are paid less than men, has become an important public discussion. While much of the focus has been on the corporate sector, a new study that looked at executive compensation at nonprofit organizations found that women earn 8.9% less than men with the gap becoming greater when there is room for salary negotiations.
The study co-authored by Curtis Hall, PhD, an associate professor in Drexel University's LeBow College of Business; Andrew R. Finley, assistant professor at the Robert Day School of Economics and Finance at Claremont McKenna College; and LeBow College of Business doctoral student Amanda R. Marino, analyzed data from IRS ...
2021-05-05
A multidisciplinary team of researchers from INRAP, CNRS, the universities of Ottawa, Rennes 2, Toulouse III Paul Sabatier and the Max Planck Institute has recognised the soldiers of the last battles of the siege of Rennes in 1491. These are the only witnesses of the forces involved in the conflict between the armies of Duchess Anne of Brittany and the King of France. This research and its methodology are currently the subject of two articles in the PLOS ONE review.
The excavation of the Jacobins convent in Rennes
From 2011 to 2013, a team from INRAP excavated the convent of the Jacobins, site of the future congress centre in Rennes Métropole, giving rise to numerous scientific ...
2021-05-05
New Haven, Conn. -- A Yale-led study reveals that new medicines and vaccines approved for use in the United States are often unavailable in countries that hosted their clinical trials, suggesting that the benefits of drug research are not being shared equitably among populations that participate in testing.
The study, published May 5 in JAMA Network Open, covers 34 novel drugs sponsored by large pharmaceutical companies that the U.S. Food and Drug Administration (FDA) approved between 2012 and 2014. Approvals were made on the basis of a total of 898 trials that were held in the United States and 70 other countries worldwide.
By analyzing the 563 trials for which location data was available, the researchers found that, five years after approval in the United States, only 15% of the drugs ...
2021-05-05
By discovering a potential new cellular mechanism for migraines, researchers may have also found a new way to treat chronic migraine.
Amynah Pradhan, associate professor of psychiatry at the University of Illinois Chicago, is the senior author of the study, whose goal was to identify a new mechanism of chronic migraine, and propose a cellular pathway for migraine therapies. The study, "Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition, is published in eLife.
Pradhan, whose research focus is on the neurobiology of pain and headache, explained that the dynamic process of routing and rerouting connections among nerve ...
2021-05-05
PHILADELPHIA-- It turns out that not all build-ups of tau protein are bad, and a team of researchers from the Perelman School of Medicine at the University of Pennsylvania developed a method to show that. Using mammalian cell models, the researchers combined extremely high-resolution microscopy with machine learning to show that tau actually forms small aggregates when a part of the body's normal physiology. Through this, they could distinguish between the aggregates occurring under healthy conditions from the ones associated with neurological diseases, potentially opening the door to screening for treatments that ...
2021-05-05
Scientists from Russia and Italy studied a new axis of the pathway that prevents the development of liver fibrosis. The role of GILZ protein in curbing the disease progression was shown in a study using mice models and confirmed by clinical data. These findings can be used in the treatment of liver fibrosis in humans. The research was published in the journal Cell Death & Disease.
Fibrosis combines an overgrowth of connective tissue and a decline in the liver function that can be caused by a viral infection, alcohol intoxication, autoimmune diseases or other liver disorders. If left untreated, fibrosis can lead to cirrhosis and even death. ...
2021-05-05
LOS ALAMOS, N.M., May 5, 2021-- A massive collaborative research project covered in the journal Nature this week offers projections to the year 2100 of future sea-level rise from all sources of land ice, offering the most complete projections created to date.
"This work synthesizes improvements over the last decade in climate models, ice sheet and glacier models, and estimates of future greenhouse gas emissions," said Stephen Price, one of the Los Alamos scientists on the project. "More than 85 researchers from various disciplines, including our team at Los Alamos National Laboratory, produced sea-level rise projections based on the most recent ...
2021-05-05
Sea ice cover in the Southern Hemisphere is extremely variable, from summer to winter and from millennium to millennium, according to a University of Maine-led study. Overall, sea ice has been on the rise for about 10,000 years, but with some exceptions to this trend.
Dominic Winski, a research assistant professor at the UMaine Climate Change Institute, spearheaded a project that uncovered new information about millennia of sea ice variability, particularly across seasons, in the Southern Hemisphere by examining the chemistry of a 54,000-year-old South Pole ice core.
The Southern Ocean experiences the largest seasonal ...
2021-05-05
ARLINGTON, TX (May 5, 2021) -- Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of retinal diseases, is featuring multiple scientific presentations highlighting its groundbreaking research on optical gene delivery for vision restoration and OCT-guided electrophysiology platforms for characterization of retinal degeneration and assessment of efficacy of cell-gene therapy at the 2021 ARVO annual (virtual) meeting, May 1-7.
ARVO, the Association for Research in Vision and Ophthalmology, is the largest eye and vision research organization in the world with nearly 11,000 members in more than 75 countries.
Nanoscope's lead product is an optogenetic ...
LAST 30 PRESS RELEASES:
[Press-News.org] 340B hospitals offer more assistance removing barriers to medication access
New study shows more pharmacy medication access services available at some hospitals